EMQCX
Price
$7.55
Change
+$0.03 (+0.40%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

EMQCX vs RNWFX

Header iconEMQCX vs RNWFX Comparison
Open Charts EMQCX vs RNWFXBanner chart's image
Ashmore Emerging Markets Active Eq C
Price$7.55
Change+$0.03 (+0.40%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
EMQCX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
EMQCX vs. RNWFX commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EMQCX is a Buy and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. EMQCX (21.8M). RNWFX pays higher dividends than EMQCX: RNWFX (1.51) vs EMQCX (1.05). EMQCX was incepted earlier than RNWFX: EMQCX (8 years) vs RNWFX (23 years). EMQCX is a more actively managed with annual turnover of: 189.00 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than EMQCX: RNWFX (250) vs EMQCX (1000). EMQCX annual gain was more profitable for investors over the last year : 12.82 vs. RNWFX (5.86). RNWFX return over 5 years is better than : 14.39 vs. EMQCX (-29.38).
EMQCXRNWFXEMQCX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years23 years-
Gain YTD10.8714.549239%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets21.8M62.2B0%
Annual Yield % from dividends1.051.5170%
Returns for 1 year12.825.86219%
Returns for 3 years-11.95-5.10234%
Returns for 5 years-29.3814.39-204%
Returns for 10 yearsN/A42.67-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics